Literature DB >> 16460541

Outcome of inappropriate empirical antibiotic therapy in patients with Staphylococcus aureus bacteraemia: analytical strategy using propensity scores.

S-H Kim1, W-B Park, C-S Lee, C-I Kang, J-W Bang, H-B Kim, N-J Kim, E-C Kim, M D Oh, K-W Choe.   

Abstract

Patients with Staphylococcus aureus bacteraemia (SAB) who received either inappropriate or appropriate empirical therapy were compared by using two risk stratification models: (1) a cohort study using a propensity score to adjust for confounding by empirical treatment assignment; and (2) a propensity-matched case-control study. Inappropriate empirical therapy was modelled on the basis of patient characteristics, and included in the multivariate model to adjust for confounding. For case-matching analysis, patients with inappropriate empirical therapy (cases) were matched to those with appropriate empirical therapy (controls) on the basis of the propensity score (within 0.03 on a scale of 0-1). In total, 238 patients with SAB were enrolled in the cohort study. Characteristics associated with inappropriate empirical therapy were methicillin resistance, underlying haematological malignancy, no history of colonisation with methicillin-resistant S. aureus, and a long hospital stay before SAB. These variables were included in the propensity score, which had an area under the receiver operating characteristics curve of 85%. In the cohort study, SAB-related mortality was 39% (45/117) for inappropriate empirical therapy vs. 28% (34/121) for appropriate empirical therapy (odds ratio (OR) 1.60; 95% CI 0.93-2.76). After adjustment for independent predictors for mortality and the propensity score, inappropriate empirical therapy was not associated with mortality (adjusted OR 1.39; 95% CI 0.62-3.15). In the matched case-control study (50 pairs), SAB-related mortality was 32% (16/50) for inappropriate empirical therapy and 28% (14/50) for appropriate empirical therapy (McNemar's test; p 0.85; OR 1.15; 95% CI 0.51-2.64). In conclusion, inappropriate empirical therapy resulted in only a slight tendency towards increased mortality in patients with SAB.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16460541     DOI: 10.1111/j.1469-0691.2005.01294.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  23 in total

1.  Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis.

Authors:  Pilar Retamar; María M Portillo; María Dolores López-Prieto; Fernando Rodríguez-López; Marina de Cueto; María V García; María J Gómez; Alfonso Del Arco; Angel Muñoz; Antonio Sánchez-Porto; Manuel Torres-Tortosa; Andrés Martín-Aspas; Ascensión Arroyo; Carolina García-Figueras; Federico Acosta; Juan E Corzo; Laura León-Ruiz; Trinidad Escobar-Lara; Jesús Rodríguez-Baño
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

Review 2.  Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis.

Authors:  Mical Paul; Vered Shani; Eli Muchtar; Galia Kariv; Eyal Robenshtok; Leonard Leibovici
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

3.  Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia.

Authors:  Sung-Han Kim; Kye-Hyung Kim; Hong-Bin Kim; Nam-Joong Kim; Eui-Chong Kim; Myoung-don Oh; Kang-Won Choe
Journal:  Antimicrob Agents Chemother       Date:  2007-11-05       Impact factor: 5.191

4.  Direct bacterial identification in positive blood cultures by use of two commercial matrix-assisted laser desorption ionization-time of flight mass spectrometry systems.

Authors:  Jonathan H K Chen; Pak-Leung Ho; Grace S W Kwan; Kevin K K She; Gilman K H Siu; Vincent C C Cheng; Kwok-Yung Yuen; Wing-Cheong Yam
Journal:  J Clin Microbiol       Date:  2013-03-20       Impact factor: 5.948

5.  Coagulase-negative staphylococcal bacteremia: risk factors for mortality and impact of initial appropriate antimicrobial therapy on outcome.

Authors:  S Y Park; K H Kwon; J-W Chung; H J Huh; S L Chae
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-04-01       Impact factor: 3.267

6.  Treatment with fluoroquinolones or with beta-lactam-beta-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-beta-lactamase-producing Klebsiella species in hospitalized patients.

Authors:  Kenneth M Wener; Vered Schechner; Howard S Gold; Sharon B Wright; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2010-03-08       Impact factor: 5.191

7.  Association of methicillin-resistant Staphylococcus aureus (MRSA) USA300 genotype with mortality in MRSA bacteremia.

Authors:  Russell R Kempker; Monica M Farley; Janine L Ladson; Sarah Satola; Susan M Ray
Journal:  J Infect       Date:  2010-09-22       Impact factor: 6.072

8.  Evaluation of MRSASelect (™) chromogenic medium for the early detection of methicillin-resistant Staphylococcus aureus from blood cultures.

Authors:  Kanchana Manickam; Andrew Walkty; Philippe Rs Lagacé-Wiens; Heather Adam; Barbara Swan; Brenda McAdam; Peter Pieroni; Michelle Alfa; James A Karlowsky
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

9.  Delay in the administration of appropriate antimicrobial therapy in Staphylococcus aureus bloodstream infection: a prospective multicenter hospital-based cohort study.

Authors:  A J Kaasch; S Rieg; J Kuetscher; H-R Brodt; T Widmann; M Herrmann; C Meyer; T Welte; P Kern; U Haars; S Reuter; I Hübner; R Strauss; B Sinha; F M Brunkhorst; M Hellmich; G Fätkenheuer; W V Kern; H Seifert
Journal:  Infection       Date:  2013-03-29       Impact factor: 3.553

10.  Empiric antibiotic therapy for Staphylococcus aureus bacteremia may not reduce in-hospital mortality: a retrospective cohort study.

Authors:  Marin L Schweizer; Jon P Furuno; Anthony D Harris; J Kristie Johnson; Michelle D Shardell; Jessina C McGregor; Kerri A Thom; George Sakoulas; Eli N Perencevich
Journal:  PLoS One       Date:  2010-07-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.